  |
AUDIENCE: Pharmacy, Health Professional, Patient ISSUE: B. Braun Medical Inc. is voluntarily recalling one lot of 1g Cefepime for Injection USP and Dextrose Injection USP (Lot H3A744, catalog 3193-11) to the consumer level. The 1g Cefepime for Injection USP and Dextrose Injection USP lot has been found to contain visible organic particulate matter in a reserve sample unit. Visible particulate matter, including metals, and organic material such as cotton fibers or hair, may illicit inflammatory responses, both chronic and acute, and may be life threatening (e.g. systemic inflammatory response syndrome (SIRS and / or anaphylaxis). If a right to left cardiac shunt is present, the particulate may lead to arterial emboli and result in stroke, myocardial infarction, respiratory failure, and loss of renal and hepatic function or tissue necrosis. Other adverse effects associated with intravenous injection of particulate matter include foreign body granulomata, particularly in the lungs, and local irritation of blood vessels. B.Braun has not received any reports of adverse events related to this lot to date. BACKGROUND: The product is used as a cephalosporin antibacterial indicated in the treatment of infections caused by susceptible strains of designated microorganisms. The product is packaged in a Duplex single dose intravenous, plastic container with 24 units per case. The affected lot H3A744, which expires January 2015, was distributed nationwide to licensed distributors, hospitals and pharmacies, and distributed to customers between the dates of February 4, 2013 and March 1, 2013 RECOMMENDATION: Patients reporting any problems that may be related to the use of this product should be advised to contact a physician and report all issues to B.Braun at 1-800-854-6851. B.Braun is notifying its distributors and customers by written, return receipt letters and is arranging for return of all recalled product. Distributors and customers that have inventory of the 1g Cefepime for Injection USP and Dextrose Injection USP of lot H3A744 should discontinue use immediately and contact B.Braun’s Customer Support Department at 1-800-227-2862, Monday through Friday, 8 a.m. to 7 p.m. EST for instructions for returning the affected product and to arrange for replacement product. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: Read the MedWatch Safety Alert, including links to the Firm Press Release at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm371031.htm Cefepime For Injection, USP And Dextrose Injection, USP By B. Braun Medical Inc.: Recall - Visible Particulate Matter
You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
